Diaceutics lifted as it exceeds expectations

By
0 mins. to read
Diaceutics lifted as it exceeds expectations
Master Investor Magazine

Master Investor Magazine 58Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

The share price of AIM-listed data analytics business Diaceutics (LON:DXRX) improved by 11.72% to 113.95p (as of 14:30 GMT) after revenues for the year ended 31st December climbed by 28%. Adjusted EBITDA was also ahead of expectations as it rose by 40% over the period.

CEO Peter Keeling commented: “We are pleased to have delivered on both our operational and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Group. 2019 was a key year in expanding our global footprint and deepening our service relationships with key clients and their therapy brands. These results provide a solid base for 2020 and the launch of our Nexus platform later in 2020“.

On 30th July at 1pm we’ll be holding the next live Q&A webinar with the Master Investor himself, Jim Mellon. Please share a question for Jim below and we’ll try to answer as many as possible in the live webinar. Sign up for the webinar here.

Are you interested in joining Jim's webinar?


Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *